Days after the FDA finally accepted the application to review its peanut allergy immunotherapy, Aimmune laid out positive pivotal study data from its European Phase III study on Monday, paving the way for an EMA marketing application by mid-2019.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,